Ovid Therapeutics (STU:1OT) Cyclically Adjusted FCF per Share: €-0.77 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1OT Ovid Therapeutics Inc STU:1OT
38 GF Score
Price €2.42
GF Value €0.85
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ovid Therapeutics Cyclically Adjusted FCF per Share?

Ovid Therapeutics STU:1OT +2.54% 38 Cyclically Adjusted FCF per Share is €-0.77 as of Jun. 2026. GuruFocus rates STU:1OT with a GF Score™ of 38/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ovid Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.077. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.77 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-16), Ovid Therapeutics's current stock price is €2.42. Ovid Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.77. Ovid Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Ovid Therapeutics  (STU:1OT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ovid Therapeutics Cyclically Adjusted FCF per Share Related Terms


Ovid Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics Cyclically Adjusted FCF per Share Chart

Ovid Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.70

Ovid Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.76 -0.70 -0.76 -0.77

STU:1OT vs SGMT, CABA, QTTB: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ovid Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:1OT
38GF Score
Ovid Therapeutics Inc STU:1OT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ovid Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.077/333.9520*333.9520
=-0.077

Current CPI (Jun. 2026) = 333.9520.

Ovid Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.214 241.428 -0.296
201612 -0.280 241.432 -0.387
201703 -0.274 243.801 -0.375
201706 -0.296 244.955 -0.404
201709 -0.319 246.819 -0.432
201712 -0.306 246.524 -0.415
201803 -0.428 249.554 -0.573
201806 -0.409 251.989 -0.542
201809 -0.354 252.439 -0.468
201812 -0.392 251.233 -0.521
201903 -0.376 254.202 -0.494
201906 -0.271 256.143 -0.353
201909 -0.224 256.759 -0.291
201912 -0.312 256.974 -0.405
202003 -0.308 258.115 -0.398
202006 -0.275 257.797 -0.356
202009 -0.022 260.280 -0.028
202012 -0.187 260.474 -0.240
202103 2.030 264.877 2.559
202106 -0.238 271.696 -0.293
202109 -0.136 274.310 -0.166
202112 -0.157 278.802 -0.188
202203 -0.260 287.504 -0.302
202206 -0.196 296.311 -0.221
202209 -0.182 296.808 -0.205
202212 -0.124 296.797 -0.140
202303 -0.161 301.836 -0.178
202306 -0.155 305.109 -0.170
202309 -0.133 307.789 -0.144
202312 -0.155 306.746 -0.169
202403 -0.217 312.332 -0.232
202406 -0.188 314.175 -0.200
202409 -0.190 315.301 -0.201
202412 -0.135 315.605 -0.143
202503 -0.134 319.799 -0.140
202506 -0.058 322.561 -0.060
202509 -0.154 324.800 -0.158
202512 -0.109 324.054 -0.112
202603 -0.088 330.213 -0.089
202606 -0.077 333.952 -0.077

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.77 mean?
Ovid Therapeutics (STU:1OT) has a Cyclically Adjusted FCF per Share of €-0.77 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ovid Therapeutics and its competitors.
Is Ovid Therapeutics' Cyclically Adjusted FCF per Share too high?
Ovid Therapeutics' current Cyclically Adjusted FCF per Share is €-0.77. Overall, Ovid Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Cyclically Adjusted FCF per Share compare to SGMT and CABA?
Ovid Therapeutics' Cyclically Adjusted FCF per Share of €-0.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current Cyclically Adjusted FCF per Share is €-0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (STU:1OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €2.42 — trading 184.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.77. Ovid Therapeutics' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ovid Therapeutics (STU:1OT), the current Cyclically Adjusted FCF per Share is €-0.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ovid Therapeutics (STU:1OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued. The current stock price of €2.42 is trading 184.7% above its estimated GF Value™ of €0.85. GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:1OT:

  • Cyclically Adjusted FCF per Share: €-0.77
  • GF Value™: €0.85 vs. price of €2.42 (184.7% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the STU:1OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ovid Therapeutics Business Description

Other Exchanges OVID:USA1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
38GF Score

Get the complete analysis for STU:1OT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price
€0.85
GF Value